A joint think tank from three research institutions has achieved a significant single milestone in developing a weight-loss maintenance medicine.
Many health problems can be solved by reducing the weight of the human body. American scientists have found a unique solution to this problem, with the help of which weight loss can be brought about with the help of normal diet.
Interestingly researchers at UT Health San Antonio, along with collaborators from the University of Pennsylvania and Cornell University, successfully, have prepared a small-molecule drug called CPACC that limits magnesium transport in cellular power plants called mitochondria.
Durring research, this medicine has been shown to prevent weight gain and adverse liver changes in mice on a high-sugar, high-fat diet. It is fact that by reducing magnesium transport in the mitochondria, the drug enhances metabolism of sugar and fat, resulting in slimmer and healthier mice with no evidence of fatty liver disease.
The researchers have filed a patent application for the drug, which has potential implications in reducing the risk of cardiometabolic diseases and liver cancer.
With the help of this drug, the severity of many other related diseases can also be reduced but a little caution is required.
A health think tank is preparing to launch a clinical trial of a drug derived from this research.